Proof-of-principle that a decoy virus protects oncolytic measles virus against neutralizing antibodies

BACKGROUND: Attenuated oncolytic measles virus (OMV) is a promising antitumor agent in early-phase clinical trials. However, pre-existing immunity against measles might be a hurdle for OMV therapy. METHODS: OMV was inactivated with short-wavelength ultraviolet light (UV-C). Loss of replication and o...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chun, Goß, Annika Verena, Dorneburg, Carmen, Debatin, Klaus-Michael, Wei, Jiwu, Beltinger, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933358/
https://www.ncbi.nlm.nih.gov/pubmed/29750140
http://dx.doi.org/10.2147/OV.S150637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933358/
https://www.ncbi.nlm.nih.gov/pubmed/29750140
http://dx.doi.org/10.2147/OV.S150637

Ejemplares similares